DA Davidson Upgrades Imperva (IMPV) to Buy
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Needham & Company Cuts Price Target on Imperva (IMPV) Following 3Q
November 4, 2016 8:21 AM EDTNeedham & Company maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $43.00 (from $64.00), following the company's 3Q earnings report. After the material guide-down last quarter, the results for IMPV were a solid beat, with $68.4m and $0.08 EPS well above $63.2m and ($0.16) loss per share consensus. CY16 was... More
Evercore ISI Upgrades Imperva (IMPV) to Buy
November 4, 2016 7:13 AM EDTEvercore ISI upgraded Imperva (NYSE: IMPV) from Hold to Buy.
For an analyst ratings summary and ratings history on Imperva click here. For more ratings news on Imperva click here.
Shares of Imperva closed at $35.10 yesterday.
... MoreImperva (IMPV) Tops Q3 EPS by 24c, Plans to Remain Standalone Compnay
November 3, 2016 4:44 PM EDTImperva (NYSE: IMPV) reported Q3 EPS of $0.08, $0.24 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $63.1 million.
GUIDANCE:
Imperva sees FY2016 EPS of ($0.38)-($0.35), versus the consensus of ($0.80). Imperva sees FY2016 revenue of $255.1-257.1 million, versus the consensus of $250.2 million.
Conclusion of Strategic Alternatives Review Process
Imperva announced today that its Board of Directors has concluded its previously announced review of strategic alternatives to enhance... More